Background: The HEMO Study was a randomized clinical trial designed to determine
whether increasing hemodialysis dose above current standards, or using high-flux membranes,
would improve patient outcome. The primary results of the trial showed no statistically
significant effects of either dialysis dose or membrane flux on the primary outcome of
mortality. Methods: This report examines the implications of secondary analyses involving
subgroups and secondary outcome measures for the overall interpretation of the trial.
Results and Conclusions: The secondary analyses of the HEMO Study do not alter the conclusions
of the primary analysis: In the context of conventional three times per week
hemodialysis, neither the high-flux nor high-dose interventions substantially improved
patient outcome compared to low-flux and standard-dose levels. However, certain secondary
results from the trial are consistent with the hypothesis of subtle effects that may be magnified
by more intensive therapies that extend beyond the limits of conventional three times
per week dialysis. This hypothesis will be addressed by a pair of new randomized trials
sponsored by the National Institute of Digestive and Kidney Disease (NIDDK), which will
compare six times per week daily and nocturnal therapies with conventional three times per
Article / Publication Details
Published online: 5/3/2005
Cover Date: 2005
Number of Print Pages: 14
Number of Figures: 0
Number of Tables: 0
ISBN: 978-3-8055-7938-4 (Print)
eISBN: 978-3-318-01222-4 (Online)
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.